Elsevier

Drug Discovery Today

Volume 9, Issue 4, 15 February 2004, Pages 161-162
Drug Discovery Today

Update
Prediction of blood–brain barrier penetration: are we missing the point?

https://doi.org/10.1016/S1359-6446(03)02961-1Get rights and content

References (10)

  • U. Norinder et al.

    Computational approaches to the prediction of the blood–brain distribution

    Adv. Drug Deliv. Rev.

    (2002)
  • D.E. Clark

    In silico prediction of blood–brain barrier permeation

    Drug Discov. Today

    (2003)
  • J. Kelder

    Polar molecular surface as a dominating determinant for oral absorption and brain penetration of drugs

    Pharm. Res.

    (1999)
  • H. Van de Waterbeemd

    Lipophilicity in PK design: methyl, ethyl, futile

    J. Comput.-Aided Mol. Des.

    (2001)
  • E.C. de Lange et al.

    Considerations in the use of cerebrospinal fluid pharmacokinetics to predict brain target concentrations in the clinical setting: implications of the barriers between blood and brain

    Clin. Pharmacokinet.

    (2002)
There are more references available in the full text version of this article.

Cited by (68)

  • Drug-delivery nanocarriers to cross the blood-brain barrier

    2016, Nanobiomaterials in Drug Delivery: Applications of Nanobiomaterials
  • Single compartment drug delivery

    2014, Journal of Controlled Release
    Citation Excerpt :

    A review of successful CNS drugs by Pajouhesh and Lenz identified several physicochemical properties of successful drugs (i.e. molecular weight < 500 Da, logP < 5, hydrogen bonding characteristics, and molecule flexibility) [107]. Modulating lipophilicity of drugs allows for passive diffusion of compounds across the BBB using the plasma membrane as a pathway [108–110]. Since this mechanism relies on passive diffusion, concentrations in the brain and circulation reach equilibrium, usually resulting in low brain concentrations and high systemic exposure.

  • In silico prediction of unbound brain-to-plasma concentration ratio using machine learning algorithms

    2011, Journal of Molecular Graphics and Modelling
    Citation Excerpt :

    However, for drugs targeting proteins in the central nervous system (CNS) brain exposure may be the biggest hurdle to overcome in the drug discovery process [1]. In recent years, it has been observed [10,11] that Kp,brain or log BB may not reflect the relevant drug exposure in the brain since it is highly influenced by the relative binding affinity of compounds to plasma proteins and brain tissue [3]. It was highlighted that the pharmacological efficacy of a drug in the CNS is not dependent on the total but on the free drug concentration in the brain [3,12].

View all citing articles on Scopus
View full text